Genprex 10-Q: Persistent Material Weaknesses, Going Concern Reiterated, and New Nasdaq MVLS Delisting Risk
GNPX sits 25% above its 52-week low of $4.
Summary
Genprex's Q2 2026 10-Q reiterates going concern doubts, confirms unremediated material weaknesses, and flags a new Nasdaq delisting risk from the pending MVLS rule.
Key Events · Earnings and Guidance · GNPX
-
Material Weaknesses Unremediated
Disclosure controls and procedures remain ineffective due to lack of segregation of duties and insufficient accounting personnel depth for complex transactions.
-
Going Concern Reiterated
Substantial doubt about ability to continue as a going concern; cash of $15.15 million funds operations into H2 2027.
-
New Nasdaq MVLS Delisting Risk
Market value of listed securities is below $5 million; if Nasdaq's pending MVLS rule becomes effective, the company could face immediate delisting without cure period.
-
Continued ATM Dilution
Sold 353,095 shares for $15.6 million net proceeds in H1 2026, plus 241,000 shares for $1.53 million after quarter-end.
Analysis · GNPX · Life Sciences
Genprex's Q2 2026 10-Q confirms that material weaknesses in internal controls remain unremediated and reiterates substantial doubt about its ability to continue as a going concern. The company also discloses a new delisting risk: its market value of listed securities is below $5 million, which could trigger immediate delisting under Nasdaq's pending MVLS rule. Cash of $15.15 million funds operations into H2 2027, but the company continues to rely on dilutive ATM sales.
At the time of this filing, GNPX was trading at $5.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $4.00 to $1,210.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.